TY  - JOUR
AU  - Nicolay, Jan
AU  - Melchers, Susanne
AU  - Albrecht, Jana D
AU  - Assaf, Chalid
AU  - Dippel, Edgar
AU  - Stadler, Rudolf
AU  - Wehkamp, Ulrike
AU  - Wobser, Marion
AU  - Zhao, Jing
AU  - Burghaus, Ina
AU  - Schneider, Sven
AU  - Gülow, Karsten
AU  - Goerdt, Sergij
AU  - Schürch, Christian M
AU  - Utikal, Jochen
AU  - Krammer, Peter
TI  - Dimethyl fumarate treatment in relapsed and refractory cutaneous T cell lymphoma - a multicenter phase II study.
JO  - Blood
VL  - 142
IS  - 9
SN  - 0006-4971
CY  - Washington, DC
PB  - American Society of Hematology
M1  - DKFZ-2023-01023
SP  - 794-805
PY  - 2023
N1  - #EA:A370#LA:D030# / 2023 Aug 31;142(9):794-805
AB  - Targeted therapies for cutaneous T-cell lymphoma (CTCL) are limited and curative approaches are lacking. Furthermore, relapses and drug induced side effects are major challenges in the therapeutic management of CTCL patients creating an urgent need for new, effective therapies. Pathologic constitutive NF-κB activity leads to apoptosis resistance in CTCL cells and thus represents a promising therapeutic target in CTCL. In a preclinical study we showed the potential of dimethyl fumarate (DMF) to block NF-κB and specifically kill CTCL cells (Nicolay et al.: Blood 2016). To translate these findings into a clinical setting, we performed a multicentric phase II study evaluating oral DMF therapy in 25 patients with CTCL stage Ib-IV over 24 weeks (EudraCT number 2014-000924-11/NCT number NCT02546440). Endpoints were safety and efficacy. We evaluated skin involvement (mSWAT), pruritus, quality of life and blood involvement if applicable as well as translational data. In the skin, 7/23 patients (30.4
LB  - PUB:(DE-HGF)16
C6  - pmid:37217183
DO  - DOI:10.1182/blood.2022018669
UR  - https://inrepo02.dkfz.de/record/276211
ER  -